Pub Date : 2024-10-20Epub Date: 2024-09-05DOI: 10.1097/CM9.0000000000003279
Zhiqiang Zhang, Yasong Wang, Jun Wang, Xiaofan Cao, Miaohan Qiu, Xiaoxiang Tian, Yaling Han, Xiaozeng Wang
{"title":"In-hospital outcomes of anemic patients with acute coronary syndrome receiving ticagrelor versus clopidogrel: Results of the Chinese Cardiovascular Care Improvement (CCC)-Acute Coronary Syndrome Project.","authors":"Zhiqiang Zhang, Yasong Wang, Jun Wang, Xiaofan Cao, Miaohan Qiu, Xiaoxiang Tian, Yaling Han, Xiaozeng Wang","doi":"10.1097/CM9.0000000000003279","DOIUrl":"10.1097/CM9.0000000000003279","url":null,"abstract":"","PeriodicalId":10183,"journal":{"name":"Chinese Medical Journal","volume":" ","pages":"2489-2491"},"PeriodicalIF":7.5,"publicationDate":"2024-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11479518/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142139429","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-10-20Epub Date: 2024-06-27DOI: 10.1097/CM9.0000000000002917
Xiaoxu Han, Jin Sun, Yihang Zhang, Taiyi Jiang, Qingshan Zheng, Haiyan Peng, Yao Wang, Wei Xia, Tong Zhang, Lijun Sun, Xinming Yun, Hong Qin, Hao Wu, Bin Su
Background: Ainuovirine (ANV) is a new generation of non-nucleoside reverse transcriptase inhibitor for the treatment of human immunodeficiency virus (HIV) type 1 infection. This study aimed to evaluate the population pharmacokinetic (PopPK) profile and exposure-response relationship of ANV among people living with HIV.
Methods: Plasma concentration-time data from phase 1 and phase 3 clinical trials of ANV were pooled for developing the PopPK model. Exposure estimates obtained from the final model were used in exposure-response analysis for virologic responses and safety responses.
Results: ANV exhibited a nonlinear pharmacokinetic profile, which was best described by a two-compartment model with first-order elimination. There were no significant covariates correlated to the pharmacokinetic parameters of ANV. The PopPK parameter estimate (relative standard error [%]) for clearance adjusted for bioavailability (CL/F) was 6.46 (15.00) L/h, and the clearance of ANV increased after multiple doses. The exposure-response model revealed no significant correlation between the virologic response (HIV-RNA <50 copies/mL) at 48 weeks and the exposure, but the incidence of adverse events increased with the increasing exposure ( P value of steady-state trough concentration and area under the steady-state curve were 0.0177 and 0.0141, respectively).
Conclusions: Our PopPK model supported ANV 150 mg once daily as the recommended dose for people living with HIV, requiring no dose adjustment for the studied factors. Optimization of ANV dose may be warranted in clinical practice due to an increasing trend in adverse reactions with increasing exposure.
Trial registration: Chinese Clinical Trial Registry https://www.chictr.org.cn (Nos. ChiCTR1800018022 and ChiCTR1800019041).
背景:Ainuovirine(ANV)是治疗人类免疫缺陷病毒(HIV)1型感染的新一代非核苷类逆转录酶抑制剂。本研究旨在评估ANV在HIV感染者中的群体药代动力学(PopPK)特征和暴露-反应关系:方法:汇集 ANV 1 期和 3 期临床试验的血浆浓度-时间数据,建立 PopPK 模型。从最终模型中获得的暴露估计值用于病毒学应答和安全性应答的暴露-应答分析:结果:ANV表现出非线性药代动力学特征,用一阶消除的两室模型对其进行了最佳描述。没有明显的协变量与ANV的药代动力学参数相关。CL/F的PopPK参数估计值(相对标准误差[%])为6.46 (15.00) L/h,多次给药后ANV的清除率增加。暴露-反应模型显示病毒学反应(HIV-RNA 结论)之间无显著相关性:我们的 PopPK 模型支持将 ANV 150 毫克每日一次作为 HIV 感染者的推荐剂量,无需根据研究因素调整剂量。由于不良反应有随着暴露量增加而增加的趋势,临床实践中可能需要优化ANV的剂量:中国临床试验注册中心 https://www.chictr.org.cn(编号:ChiCTR1800018022 和 ChiCTR1800019041)。
{"title":"Population pharmacokinetics of Ainuovirine and exposure-response analysis in human immunodeficiency virus-infected individuals.","authors":"Xiaoxu Han, Jin Sun, Yihang Zhang, Taiyi Jiang, Qingshan Zheng, Haiyan Peng, Yao Wang, Wei Xia, Tong Zhang, Lijun Sun, Xinming Yun, Hong Qin, Hao Wu, Bin Su","doi":"10.1097/CM9.0000000000002917","DOIUrl":"10.1097/CM9.0000000000002917","url":null,"abstract":"<p><strong>Background: </strong>Ainuovirine (ANV) is a new generation of non-nucleoside reverse transcriptase inhibitor for the treatment of human immunodeficiency virus (HIV) type 1 infection. This study aimed to evaluate the population pharmacokinetic (PopPK) profile and exposure-response relationship of ANV among people living with HIV.</p><p><strong>Methods: </strong>Plasma concentration-time data from phase 1 and phase 3 clinical trials of ANV were pooled for developing the PopPK model. Exposure estimates obtained from the final model were used in exposure-response analysis for virologic responses and safety responses.</p><p><strong>Results: </strong>ANV exhibited a nonlinear pharmacokinetic profile, which was best described by a two-compartment model with first-order elimination. There were no significant covariates correlated to the pharmacokinetic parameters of ANV. The PopPK parameter estimate (relative standard error [%]) for clearance adjusted for bioavailability (CL/F) was 6.46 (15.00) L/h, and the clearance of ANV increased after multiple doses. The exposure-response model revealed no significant correlation between the virologic response (HIV-RNA <50 copies/mL) at 48 weeks and the exposure, but the incidence of adverse events increased with the increasing exposure ( P value of steady-state trough concentration and area under the steady-state curve were 0.0177 and 0.0141, respectively).</p><p><strong>Conclusions: </strong>Our PopPK model supported ANV 150 mg once daily as the recommended dose for people living with HIV, requiring no dose adjustment for the studied factors. Optimization of ANV dose may be warranted in clinical practice due to an increasing trend in adverse reactions with increasing exposure.</p><p><strong>Trial registration: </strong>Chinese Clinical Trial Registry https://www.chictr.org.cn (Nos. ChiCTR1800018022 and ChiCTR1800019041).</p>","PeriodicalId":10183,"journal":{"name":"Chinese Medical Journal","volume":" ","pages":"2473-2482"},"PeriodicalIF":7.5,"publicationDate":"2024-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11479413/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141455677","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-10-20Epub Date: 2024-09-03DOI: 10.1097/CM9.0000000000003248
Tao Qiu, Meichen Liu, Xinhui Qiu, Tianbai Li, Weidong Le
Abstract: Parkinson's disease (PD) is a neurodegenerative disease characterized by various motor and non-motor symptoms. The complexity of its symptoms suggests that PD is a heterogeneous neurological disorder. Its pathological changes are not limited to the substantia nigra-striatal system, but gradually extending to other regions including the cerebellum. The cerebellum is connected to a wide range of central nervous system regions that form essential neural circuits affected by PD. In addition, altered dopaminergic activity and α-synuclein pathology are found in the cerebellum, further suggesting its role in the PD progression. Furthermore, an increasing evidence obtained from imaging studies has demonstrated that cerebellar structure, functional connectivity, and neural metabolism are altered in PD when compared to healthy controls, as well as among different PD subtypes. This review provides a comprehensive summary of the cerebellar pathophysiology and results from neuroimaging studies related to both motor and non-motor symptoms of PD, highlighting the potential significance of cerebellar assessment in PD diagnosis, differential diagnosis, and disease monitoring.
{"title":"Cerebellar involvement in Parkinson's disease: Pathophysiology and neuroimaging.","authors":"Tao Qiu, Meichen Liu, Xinhui Qiu, Tianbai Li, Weidong Le","doi":"10.1097/CM9.0000000000003248","DOIUrl":"10.1097/CM9.0000000000003248","url":null,"abstract":"<p><strong>Abstract: </strong>Parkinson's disease (PD) is a neurodegenerative disease characterized by various motor and non-motor symptoms. The complexity of its symptoms suggests that PD is a heterogeneous neurological disorder. Its pathological changes are not limited to the substantia nigra-striatal system, but gradually extending to other regions including the cerebellum. The cerebellum is connected to a wide range of central nervous system regions that form essential neural circuits affected by PD. In addition, altered dopaminergic activity and α-synuclein pathology are found in the cerebellum, further suggesting its role in the PD progression. Furthermore, an increasing evidence obtained from imaging studies has demonstrated that cerebellar structure, functional connectivity, and neural metabolism are altered in PD when compared to healthy controls, as well as among different PD subtypes. This review provides a comprehensive summary of the cerebellar pathophysiology and results from neuroimaging studies related to both motor and non-motor symptoms of PD, highlighting the potential significance of cerebellar assessment in PD diagnosis, differential diagnosis, and disease monitoring.</p>","PeriodicalId":10183,"journal":{"name":"Chinese Medical Journal","volume":" ","pages":"2395-2403"},"PeriodicalIF":7.5,"publicationDate":"2024-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11479504/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142124986","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-10-20Epub Date: 2024-08-26DOI: 10.1097/CM9.0000000000003246
Mei Luo, Jinsong Liu, Zhe Zhang, Jin Tao, Youxiang Chen, Xiuling Li, Xiaoping Zou, Jing Sun, Jie Jin, Huahong Wang, Lishou Xiong
{"title":"Diagnostic accuracy of a simplified tool for irritable bowel syndrome with predominant constipation in Chinese patients: A multicenter, prospective, observational study.","authors":"Mei Luo, Jinsong Liu, Zhe Zhang, Jin Tao, Youxiang Chen, Xiuling Li, Xiaoping Zou, Jing Sun, Jie Jin, Huahong Wang, Lishou Xiong","doi":"10.1097/CM9.0000000000003246","DOIUrl":"10.1097/CM9.0000000000003246","url":null,"abstract":"","PeriodicalId":10183,"journal":{"name":"Chinese Medical Journal","volume":" ","pages":"2509-2511"},"PeriodicalIF":7.5,"publicationDate":"2024-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11479474/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142055076","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Applying a trauma custom bridge system to reconstruct critical-sized femoral and tibial defects: Finite element analysis, osseointegration, and clinical outcomes.","authors":"Bingchuan Liu, Xingcai Li, Zhengguang Wang, Zhuo Chen, Fang Zhou, Zhongwei Yang, Guojin Hou, Min Liu, Kai Song, Caimei Wang, Yun Tian","doi":"10.1097/CM9.0000000000003235","DOIUrl":"10.1097/CM9.0000000000003235","url":null,"abstract":"","PeriodicalId":10183,"journal":{"name":"Chinese Medical Journal","volume":" ","pages":"2515-2517"},"PeriodicalIF":7.5,"publicationDate":"2024-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11479456/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142281172","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-10-20Epub Date: 2024-06-14DOI: 10.1097/CM9.0000000000003166
Yueqing He, Xi Huang, Sheng Gao, Meixia Zhang, Junjun Zhang
{"title":"Does the microaneurysm have to be distinguished from a similar-sized dot hemorrhage?","authors":"Yueqing He, Xi Huang, Sheng Gao, Meixia Zhang, Junjun Zhang","doi":"10.1097/CM9.0000000000003166","DOIUrl":"10.1097/CM9.0000000000003166","url":null,"abstract":"","PeriodicalId":10183,"journal":{"name":"Chinese Medical Journal","volume":" ","pages":"2504-2506"},"PeriodicalIF":7.5,"publicationDate":"2024-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11479462/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141327312","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Background: Breast cancer is ranked among the most prevalent malignancies in the Chinese female population. However, comprehensive reports detailing the latest epidemiological data and attributable disease burden have not been extensively documented.
Methods: In 2018, high-quality cancer surveillance data were recorded in 700 population-based cancer registries in China. We extracted data on female breast cancers (International Classification of Diseases, Tenth Revision [ICD-10]: C50) and estimated the incidence and mortality in 2022 according to the baseline data and corresponding trends from 2010 to 2018. Pathological types were classified according to the ICD for Oncology, 3rd Edition codes. Disability-adjusted life years (DALYs) were calculated as the sum of the years of life lost (YLLs) and years lived with disability (YLDs).
Results: In 2022, approximately 357,200 new female breast cancer cases and 75,000 deaths occurred in China, accounting for 15.59% and 7.94% of total new cancer cases and deaths, respectively. The age-standardized incidence rate (ASIR) was 33.04 per 100,000. When analyzed by pathological type, the ASIRs for papillary neoplasms, invasive breast carcinoma, rare and salivary gland-type tumors, and other types were 1.13, 29.79, 0.24, and 1.88 per 100,000, respectively. The age-standardized mortality rate (ASMR) was 6.10 per 100,000. A total of 2,628,000 DALYs were found to be attributable to female breast cancer in China, comprising 2,278,300 YLLs and 349,700 YLDs. The ASIR, ASMR, and age-standardized rate (ASR) for DALYs in urban areas were consistently higher than those in rural areas. We observed a four-fold increase in the ASIR and ASR for DALYs and an eight-fold increase in the ASMR among females over 55 years compared with those aged under 55 years.
Conclusion: These data provide invaluable insights into the latest epidemiology of female breast cancer in China and highlight the urgency for disease prevention and control strategy formulation.
{"title":"Incidence, mortality, and disability-adjusted life years of female breast cancer in China, 2022.","authors":"Kexin Sun, Bailin Zhang, Shaoyuan Lei, Rongshou Zheng, Xin Liang, Li Li, Xiaolong Feng, Siwei Zhang, Hongmei Zeng, Yifei Yao, Peiqing Ma, Shaoming Wang, Ru Chen, Bingfeng Han, Wenqiang Wei, Jie He","doi":"10.1097/CM9.0000000000003278","DOIUrl":"10.1097/CM9.0000000000003278","url":null,"abstract":"<p><strong>Background: </strong>Breast cancer is ranked among the most prevalent malignancies in the Chinese female population. However, comprehensive reports detailing the latest epidemiological data and attributable disease burden have not been extensively documented.</p><p><strong>Methods: </strong>In 2018, high-quality cancer surveillance data were recorded in 700 population-based cancer registries in China. We extracted data on female breast cancers (International Classification of Diseases, Tenth Revision [ICD-10]: C50) and estimated the incidence and mortality in 2022 according to the baseline data and corresponding trends from 2010 to 2018. Pathological types were classified according to the ICD for Oncology, 3rd Edition codes. Disability-adjusted life years (DALYs) were calculated as the sum of the years of life lost (YLLs) and years lived with disability (YLDs).</p><p><strong>Results: </strong>In 2022, approximately 357,200 new female breast cancer cases and 75,000 deaths occurred in China, accounting for 15.59% and 7.94% of total new cancer cases and deaths, respectively. The age-standardized incidence rate (ASIR) was 33.04 per 100,000. When analyzed by pathological type, the ASIRs for papillary neoplasms, invasive breast carcinoma, rare and salivary gland-type tumors, and other types were 1.13, 29.79, 0.24, and 1.88 per 100,000, respectively. The age-standardized mortality rate (ASMR) was 6.10 per 100,000. A total of 2,628,000 DALYs were found to be attributable to female breast cancer in China, comprising 2,278,300 YLLs and 349,700 YLDs. The ASIR, ASMR, and age-standardized rate (ASR) for DALYs in urban areas were consistently higher than those in rural areas. We observed a four-fold increase in the ASIR and ASR for DALYs and an eight-fold increase in the ASMR among females over 55 years compared with those aged under 55 years.</p><p><strong>Conclusion: </strong>These data provide invaluable insights into the latest epidemiology of female breast cancer in China and highlight the urgency for disease prevention and control strategy formulation.</p>","PeriodicalId":10183,"journal":{"name":"Chinese Medical Journal","volume":" ","pages":"2429-2436"},"PeriodicalIF":7.5,"publicationDate":"2024-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11479498/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142139428","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-10-20Epub Date: 2024-02-26DOI: 10.1097/CM9.0000000000002923
Yang He, Meng Zhang, Jun Tang, Wanxiu Liu, Yong Hu, Jing Shi, Hua Wang, Tao Xiong, Li Zhang, Junjie Ying, Dezhi Mu
Background: Very low birth weight (VLBW) infants are the key populations in neonatology, wherein morbidity and mortality remain major challenges. The study aimed to analyze the clinical characteristics of VLBW infants.
Methods: A retrospective cohort study was conducted in West China Second Hospital between January 2016 and December 2021. Neonates with a birth weight of <1500 g were included. Mortality, care practices, and major morbidities were analyzed, and compared with those of previous 7 years (2009-2015).
Results: Of the total 1750 VLBW, 1386 were infants born with birth weight between 1000-1499 g and 364 infants were born with weight below 1000 g; 42.9% (751/1750) required delivery room resuscitation; 53.9% (943/1750) received non-invasive ventilation only; 38.2% (669/1750) received invasive ventilation; 1517 VLBW infants received complete treatment. Among them, 60.1% (912/1517) of neonates had neonatal respiratory distress syndrome (NRDS), 28.7% (436/1517) had bronchopulmonary dysplasia (BPD), 22.0% (334/1517) had apnea, 11.1% (169/1517) had culture-confirmed sepsis, 8.4% (128/1517) had pulmonary hemorrhage, 7.6% (116/1517) had severe intraventricular hemorrhage (IVH)/periventricular leukomalacia (PVL), 5.7% (87/1517) had necrotizing enterocolitis (NEC), and 2.0% (31/1517) had severe retinopathy of prematurity. The total and in-hospital mortality rates were 9.7% (169/1750) and 3.0% (45/1517), respectively. The top three diagnoses of death among those who had received complete treatment were sepsis, NRDS, and NEC. In 2009-2015, 1146 VLBW were enrolled and 895 infants received complete treatment. The proportions of apnea, IVH, and IVH stage ≥3/PVL, were higher in 2009-2015 compared with those in 2016-2021, while the proportions of NRDS and BPD were characterized by significant increases in 2016-2021. The total and in-hospital mortality rates were 16.7% (191/1146) and 5.6% (50/895) respectively in 2009-2015.
Conclusion: Among VLBW infants born in 2016-2021, the total and in-hospital mortality rates were lower than those of neonates born in 2009-2015. Incidences of NRDS and BPD increased in 2016-2021, which affected the survival rates and long-term prognosis of VLBW.
{"title":"Mortality, morbidity, and care practices for 1750 very low birth weight infants, 2016-2021.","authors":"Yang He, Meng Zhang, Jun Tang, Wanxiu Liu, Yong Hu, Jing Shi, Hua Wang, Tao Xiong, Li Zhang, Junjie Ying, Dezhi Mu","doi":"10.1097/CM9.0000000000002923","DOIUrl":"10.1097/CM9.0000000000002923","url":null,"abstract":"<p><strong>Background: </strong>Very low birth weight (VLBW) infants are the key populations in neonatology, wherein morbidity and mortality remain major challenges. The study aimed to analyze the clinical characteristics of VLBW infants.</p><p><strong>Methods: </strong>A retrospective cohort study was conducted in West China Second Hospital between January 2016 and December 2021. Neonates with a birth weight of <1500 g were included. Mortality, care practices, and major morbidities were analyzed, and compared with those of previous 7 years (2009-2015).</p><p><strong>Results: </strong>Of the total 1750 VLBW, 1386 were infants born with birth weight between 1000-1499 g and 364 infants were born with weight below 1000 g; 42.9% (751/1750) required delivery room resuscitation; 53.9% (943/1750) received non-invasive ventilation only; 38.2% (669/1750) received invasive ventilation; 1517 VLBW infants received complete treatment. Among them, 60.1% (912/1517) of neonates had neonatal respiratory distress syndrome (NRDS), 28.7% (436/1517) had bronchopulmonary dysplasia (BPD), 22.0% (334/1517) had apnea, 11.1% (169/1517) had culture-confirmed sepsis, 8.4% (128/1517) had pulmonary hemorrhage, 7.6% (116/1517) had severe intraventricular hemorrhage (IVH)/periventricular leukomalacia (PVL), 5.7% (87/1517) had necrotizing enterocolitis (NEC), and 2.0% (31/1517) had severe retinopathy of prematurity. The total and in-hospital mortality rates were 9.7% (169/1750) and 3.0% (45/1517), respectively. The top three diagnoses of death among those who had received complete treatment were sepsis, NRDS, and NEC. In 2009-2015, 1146 VLBW were enrolled and 895 infants received complete treatment. The proportions of apnea, IVH, and IVH stage ≥3/PVL, were higher in 2009-2015 compared with those in 2016-2021, while the proportions of NRDS and BPD were characterized by significant increases in 2016-2021. The total and in-hospital mortality rates were 16.7% (191/1146) and 5.6% (50/895) respectively in 2009-2015.</p><p><strong>Conclusion: </strong>Among VLBW infants born in 2016-2021, the total and in-hospital mortality rates were lower than those of neonates born in 2009-2015. Incidences of NRDS and BPD increased in 2016-2021, which affected the survival rates and long-term prognosis of VLBW.</p>","PeriodicalId":10183,"journal":{"name":"Chinese Medical Journal","volume":" ","pages":"2452-2460"},"PeriodicalIF":7.5,"publicationDate":"2024-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11479399/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139971079","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-10-20Epub Date: 2024-09-10DOI: 10.1097/CM9.0000000000003286
Xianze Li, Tao Xue, Zixiao Li, Jianguo Zhang
{"title":"Invasive electrical nerve stimulation for post-stroke motor rehabilitation.","authors":"Xianze Li, Tao Xue, Zixiao Li, Jianguo Zhang","doi":"10.1097/CM9.0000000000003286","DOIUrl":"10.1097/CM9.0000000000003286","url":null,"abstract":"","PeriodicalId":10183,"journal":{"name":"Chinese Medical Journal","volume":" ","pages":"2495-2497"},"PeriodicalIF":7.5,"publicationDate":"2024-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11479480/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142281184","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}